. . . searching for a comparable, I'd look to Biomarin (BRMN) . . . orphan drugs, a $7 billion market cap, considered to be a takeout target, has a bit less than half of ALXN's revenues . . . so at twice the market cap ($14 billion), you're looking at roughly $75 per share . . . but , alas, only mr. market knows for sure . . . good luck . . .